John Haldi, 84, had early-stage Alzheimer's disease when he began a local Aduhelm drug study in 2020 lasting three years. The drug wasn't approved but similar ones now are. By July with testing, a neurologist told Haldi he "no longer has amyloid plaques," to meet Alzheimer's disease diagnosis. He still struggles with short-term memory loss, but Haldi is traveling, finishing puzzles and playing his trombone.